Ceftibuten is a new, third-generation oral cephalosporin currently being reviewed for approval by the FDA. The drug, which will likely be available in both suspension and tablet formulations, has proven clinical efficacy in treating adults and children with respiratory or urogenital infections. Ceftibuten has increased stability to beta lactamase hydrolysis, which enhances its antimicrobial activity to gram-negative community-acquired pathogens. Its oral bioavailability is superior to other currently available expanded-spectrum oral cephalosporins. Ceftibuten's absorption characteristics and relatively low incidence of adverse effects in clinical trials make it a useful alternative to other drugs used to treat a variety of community-acquired infections.
|Original language||English (US)|
|Number of pages||7|
|State||Published - 1995|
ASJC Scopus subject areas
- Pharmaceutical Science